Shorter Radiation Course Matches Standard for Breast Cancer Lymphedema Risk
A Danish phase III trial finds hypofractionated radiotherapy over 3 weeks is as safe as the standard 5-week course for breast cancer patients.
Summary
A large Danish clinical trial involving nearly 2,900 breast cancer patients found that a shorter, hypofractionated radiotherapy schedule — 40 Gy over 3 weeks — was just as safe as the traditional 5-week course when it came to arm lymphedema risk. After 3 years, lymphedema rates were 8% versus 9.4%, with no meaningful difference. Cancer recurrence, breast cancer mortality, and all-cause mortality were also equivalent between groups. These findings, published in the Journal of Clinical Oncology, support broader adoption of the shorter schedule, which reduces treatment burden, improves convenience for patients, and lowers healthcare costs. Results align with a similar French trial and may prompt practice changes at centers still using standard fractionation.
Detailed Summary
Breast cancer treatment often requires radiotherapy following surgery, and the scheduling of that radiation — how many sessions over how many weeks — can significantly affect patient burden and side effects. A key concern has been lymphedema, a chronic swelling of the arm caused by lymph node disruption, which affects quality of life long after treatment ends.
The Danish Breast Cancer Group Skagen trial 1 enrolled 2,908 women with high-risk breast cancer across 17 centers between 2015 and 2021. Participants were randomized to either standard radiotherapy (50 Gy in 25 fractions over 5 weeks) or hypofractionated radiotherapy (40 Gy in 15 fractions over 3 weeks). The trial's primary endpoint was arm lymphedema incidence at 3 years.
Results showed 3-year lymphedema rates of 9.4% in the standard group versus 8% in the hypofractionated group — a statistically non-inferior outcome well within the predefined margin. Critically, there were no significant differences in locoregional recurrence, distant metastasis, breast cancer mortality, or all-cause mortality, confirming that the shorter course does not compromise cancer control.
These findings mirror the French HypoG-01 trial, which also demonstrated non-inferiority of a 3-week regimen at 5 years. Together, both trials provide strong convergent evidence supporting hypofractionation for regional node irradiation in high-risk breast cancer — an area where evidence had previously been limited despite pandemic-era adoption of the shorter schedule.
For clinical practice, the implications are clear: shorter radiation schedules reduce the number of hospital visits, lower healthcare system costs, and ease the daily treatment burden on women undergoing breast cancer therapy. Editorialists from McMaster University called these results a prompt for centers still using conventional fractionation to update their protocols. The 3-year follow-up window, however, means longer-term outcomes still warrant monitoring.
Key Findings
- 3-week hypofractionated radiotherapy matched 5-week standard for arm lymphedema risk in breast cancer women
- 3-year lymphedema rates: 8% (hypofractionated) vs 9.4% (standard) — no significant difference
- No differences in cancer recurrence, breast cancer mortality, or all-cause mortality between groups
- Findings replicate the French HypoG-01 trial, strengthening evidence for shorter radiotherapy schedules
- Shorter course reduces patient hospital visits and healthcare costs without sacrificing safety or efficacy
Methodology
This is a news report summarizing a peer-reviewed phase III randomized controlled trial published in the Journal of Clinical Oncology. The Danish Skagen trial 1 enrolled 2,908 patients across 17 centers, representing high-quality Level 1 evidence. The source, MedPage Today, is a credible medical news outlet targeting clinicians.
Study Limitations
Follow-up is limited to 3 years; longer-term lymphedema rates and late radiation toxicities such as brachial neuropathy require continued monitoring. The article summary is truncated and may omit subgroup analyses or secondary endpoints. Readers should consult the full Journal of Clinical Oncology publication for complete data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: